10 Stocks with Potential to Explode in 2025

7. Moderna, Inc. (NASDAQ:MRNA)

Average Upside Potential: ~105.1%

Number of Hedge Fund Holders: 44

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company, which is engaged in providing messenger RNA medicines in the US, Europe, and internationally.  The company has made progress in 2024 through its late-stage pipeline and cost-reduction efforts. Its team successfully filed 3 Biologics License Applications in the final months of the year and decreased its costs by 27% as compared to 2023. Entering 2025, Moderna, Inc. (NASDAQ:MRNA) remains focused on fueling sales, providing up to 10 product approvals through 2027, and expanding the cost efficiencies throughout the business. By the end of 2025, the company targets removing ~$1 billion in costs.

Given the healthy momentum in its late-stage pipeline, Moderna, Inc. (NASDAQ:MRNA) expects multiple approvals starting this year, together with key Phase 3 readouts that can support its long-term growth. Coming to the respiratory vaccines, the company has shared positive Phase 3 vaccine efficacy and immunogenicity data for its next-generation COVID-19 vaccine (mRNA-1283). Moderna, Inc. (NASDAQ:MRNA) filed for regulatory approval of mRNA-1283 with the FDA through a priority review voucher. The FDA accepted the company’s Biologics License Application (BLA) for mRNA-1283 and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 31, 2025. Moderna, Inc. (NASDAQ:MRNA) has also received regulatory approval for its RSV (Respiratory syncytial virus) vaccine mRESVIA (mRNA-1345) for adults aged 60 years and older in 2024. It shared positive Phase 3 data for mRNA-1345 in high-risk adults aged 18-59.